Infant Bacterial Therapeutics Valuation
Is 9IB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9IB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9IB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9IB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9IB?
Key metric: As 9IB barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 9IB's PB Ratio? | |
|---|---|
| PB Ratio | 2.5x |
| Book | SEK 204.03m |
| Market Cap | SEK 514.61m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 57682.4x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 9IB's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.4x | ||
93M1 MPH Health Care | 0.3x | -65.7% | €105.3m |
0RX Redx Pharma | 16.6x | -22.3% | €65.0m |
HIGH Cantourage Group | 1.3x | 112.7% | €55.6m |
2FJ0 Pierrel | 3.6x | n/a | €92.8m |
9IB Infant Bacterial Therapeutics | 2.5x | n/a | €514.6m |
Price-To-Book vs Peers: 9IB is good value based on its Price-To-Book Ratio (2.5x) compared to the peer average (5.4x).
Price to Book Ratio vs Industry
How does 9IB's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 12 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 9IB is expensive based on its Price-To-Book Ratio (2.5x) compared to the European Pharmaceuticals industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is 9IB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 9IB's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
5.1%
1Y
22.9%